NCT01906372View on ClinicalTrials.gov

Acthar in Treatment of Refractory Dermatomyositis and Polymyositis

PHASE2CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

September 30, 2013

Primary Completion Date

September 30, 2015

Study Completion Date

May 31, 2016

Conditions
DermatomyositisPolymyositis
Interventions
DRUG

Adrenocorticotropic Hormone Gel

H.P. Acthar Gel 80 units will be self-administered subcutaneously twice weekly by the subject for a period of 6 months.

Trial Locations (2)

11021

North Shore LIJ Medical Center, Great Neck

15261

University of Pittsburgh, Pittsburgh

Sponsors

Collaborators (1)

Mallinckrodt
All Listed Sponsors
collaborator

Mallinckrodt

INDUSTRY

lead

Rohit Aggarwal, MD

OTHER

NCT01906372 - Acthar in Treatment of Refractory Dermatomyositis and Polymyositis | Biotech Hunter | Biotech Hunter